论文部分内容阅读
目的:探讨新氟喹诺酮类抗生素治疗呼吸道支原体感染的临床治疗效果和不良反应。方法:选取2013年1月-2014年12月东莞市寮步医院收治的100例呼吸道支原体感染患者作为研究对象,随机分为对照组和观察组,每组50例。对照组使用阿奇霉素治疗,观察组患者使用新氟喹诺酮类抗生素治疗。治疗2周后,观察对照组和观察组的临床治疗效果和不良反应发生情况。结果:治疗后,对照组临床治疗总有效率为82%,观察组临床治疗总有效率为96%,观察组临床治疗效果和不良反应发生情况明显优于对照组,差异有统计学意义(P<0.05)。结论:新氟喹诺酮类抗生素治疗呼吸道支原体感染,不仅具有显著的疗效,还具有较高的安全性,临床应用价值高。
Objective: To investigate the clinical effects and adverse reactions of new fluoroquinolone antibiotics in the treatment of respiratory tract mycoplasma infection. Methods: One hundred patients with Mycoplasma respiratory tract infection admitted from Liaobu Hospital of Dongguan City from January 2013 to December 2014 were selected and randomly divided into control group and observation group, with 50 cases in each group. The control group was treated with azithromycin, and the observation group was treated with neofluoroquinolone antibiotics. After 2 weeks of treatment, the clinical efficacy and adverse reactions of the control group and the observation group were observed. Results: After treatment, the total effective rate of clinical treatment in the control group was 82%, and the total effective rate in the observation group was 96%. The clinical efficacy and adverse reactions in the observation group were significantly better than those in the control group (P <0.05). Conclusion: The new fluoroquinolone antibiotics in the treatment of respiratory tract mycoplasma infection, not only has a significant effect, but also has high safety, high clinical value.